P53 null mice: Damaging the hypothesis?

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 452, Issue 2, 2000, Pages 149-162

  Sansom, Owen J ^a,b   Clarke, Alan R ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Mice; p53; Tumour suppressor gene

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; CARCINOGENESIS; DNA DAMAGE; GENE MUTATION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 0034683566     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(00)00089-0     Document Type: Review

References (81)

1. C Harris C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88(20):1996;442-1455.
2. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387(6630):1997;296-299.
3. Wyllie A.H., Carde P.J., Clarke A.R., Cripps K.J., Gledhill S., F Greaves M., Griffiths S., Harrison D.J., Hooper M.L., Morris R.G., Purdie C.A., Bird C.C. Apoptosis in carcinogenesis - the role of p53. Cold Spring Harbor Symp. Quant. Biol. 59:1994;403-409.
4. Agarwal M.L., Agarwal A., Taylor W.R., Stark G.R. Proc. Natl. Acad. U. S. A. 92:1995;8493-8497.
5. Prives C., Hall P.A. The p53 pathway. J. Pathol. 187(1):1999;112-126.
6. Lee S., Elenbaas B., Levinea A., Griffith J. P53 and its 14 Kda C-terminal domain recognize primary DNA-damage in the form of insertion deletion mismatches. Cell. 81(7):1995;1013-1020.
7. Janus F., Albrechtsen N., Dornreiter I., Wiesmuller L., Grosse F., Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell. Mol. Life Sci. 55(1):1999;12-27.
8. L Kirkwood T.B., Holiday R. Commitment to senescence: a model for the finite growth of diploid and transformed human fibroblasts. J. Theor. Biol. 53:1996;481-496.
9. Donehower L.A., Harvey M., Slagle B.L., Mcarthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 356(6366):1992;215-221.
10. Purdie C.A., Harrison D.J., Peter A., Dobbie L., White S., Howie S.E.M., Salter D.M., Bird C.C., Wyllie A.H., Hooper M.L., Clarke A.R. Tumor-incidence spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 9(2):1994;603-609.
11. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4(1):1994;1-7.
12. Harris C.C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329(18):1993;1318-1327.
13. Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H. Germ line p53 mutations in a familial syndrome of breast-cancer sarcomas, and other neoplasms. Science. 250(4985):1990;1233-1238.
14. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., Chang E.H., Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome Nature. 348(6303):1990;747-749.
15. Loazano G., Lui G. Mouse models dissect the role of p53 in cancer and development. Semin. Cancer Biol. 8:1998;337-344.
16. Attardi L.D., Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell. Mol. Life Sci. 55(1):1999;48-63.
17. Donehower L.A. Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Biochim. Et Biophys. Acta-Rev. Cancer. 1242(3):1996;171-176.
18. Donehower L.A., Harvey M., Vogel H., Mcarthur M., Montgomery C.A., Park S.H., Thompson T., Ford R.J., Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinog. 14(1):1995;16-22.
19. VanMeyel D.J., SanchezSweatman O.H., Kerkvliet N., Stitt L., Ramsay D.A., Khokha R., Chambers A.F., Cairncross J.G. Genetic background influences timing, morphology and dissemination of lymphomas in p53-deficient mice. Int. J. Oncol. 13(5):1998;917-922.
20. Stevens L.C., Little C.C. Spontaneous testicular teratomas in an inbred strain of mice. Proc. Natl. Acad. Sci. U. S. A. 40:1954;1080-1087.
21. Harvey M., Vogel H., Lee E.Y.H.P., Bradley A., Donehower L.A. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 55(5):1995;1146-1151.
22. Harrison D.J., Hooper M.L., Armstrong J.F., Clarke A.R. Effects of heterozygosity for the Rb-1(T19neo) allele in the mouse. Oncogene. 10(8):1995;1615-1620.
23. Lane D.P. P53: guardian of the genome. Nature. 358:1992;15-16.
24. Kondo S. Apoptotic repair of genotoxic tissue damage and the role of p53 gene. Mut. Res.-Fundam. Mol. Mech. Mutagen. 402(1-2):1998;311-319.
25. Kirkwood T.B.L., Franschi C. Is aging as complex as it would appear. Ann. NY Acad. Sci. 663:1992;412-417.
26. Modrich P., Lahue R. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu. Rev. Biochem. 65:1996;101-133.
27. Rotter V., Schwartz D., Almon E., Goldfinger N., Kapon A., Meshorer A., Donehower L.A., Levine A.J. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc. Natl. Acad. Sci. U. S. A. 90(19):1993;9075-9079.
28. Choi J., Donehower L.A. P53 in embryonic development: maintaining a fine balance. Cell. Mol. Life Sci. 55(1):1999;38-47.
29. Armstrong J.F., Kaufman M.H., Harrison D.J., Clarke A.R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5(8):1995;931-936.
30. Sah V.P., Attardi L.D., Mulligan G.J., Williams B.O., Bronson R.T., Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10(2):1995;175-180.
31. Cranston A., Bocker T., Reitmair A., Palazzo J., Wilson T., Mak T., Fishel R. Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nature Genet. 17(1):1997;114-118.
32. Toft N.J., Arends M.J., Wyllie A.H., Clarke A.R. No female embryonic lethality in mice nullizygous for Msh2 and p53. Nature Genet. 18(1):1998;17.
33. Norimura T., Nomuta S., Katsuki M., Gondo Y., Kondo S. P53 dependent apoptosis suppresses radiation induced teratogenesis. Nature Med. 2:1996;581.
34. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 378(6553):1995;206-208.
35. Luna R.M.D., Wagner D.S., Lozano G. Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature. 378(6553):1995;203-206.
36. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 95(26):1998;15608-15612.
37. Clarke A.R., Howard L.A., Harrison D.J., Winton D.J. P53, mutation frequency and apoptosis in the murine small intestine. Oncogene. 14(17):1997;2015-2018.
38. Corbet S.W., Clarke A.R., Gledhills S., Wyllie A.H. P53-dependent and -independent links between DNA-damage apoptosis and mutation frequency in ES cell. Oncogene. 18(8):1999;1537-1544.
39. Jasani B., Campbell F., Navabi N., Schmid K.W., Williams G.T. Clonal overexpression of metallothionein is induced by somatic mutation in morphologically normal colonic mucosa. J. Pathol. 184:1999;144-147.
40. Turker M.S. Estimation of mutation frequencies in normal mammalian cells and the development of cancer. Semin. Cancer Biol. 8(6):1998;407-419.
41. Winton D.J., Blount M.A., Ponder B.A.J. A clonal marker induced by mutation in mouse intestinal epithelium. Nature. 333(6172):1988;463-466.
42. Nishino H., Knoll A., Buettner V.L., Frisk C.S., Maruta Y., Haavik J., Sommer S.S. P53 wild-type and p53 nullizygous Big-Blue transgenic mice have similar frequencies and patterns of observed mutation in liver spleen and brain. Oncogene. 11(2):1995;263-270.
43. Cosentino I., Heddle J.A. A comparison of the effects of diverse mutagens at the lacZ transgene and Dlb-1 locus in vivo. Mutagenesis. 14(1):1999;113-119.
44. Buettner V.L., Nishino H., Haavik J., Knoll A., Hill K., Sommer S.S. Spontaneous mutation frequencies and spectra in p53 (+/+) and p53 (-/-) mice: a test of the guardian of the genome hypothesis in the Big Blue(R) transgenic mouse mutation detection system. Mut. Res.-Fundam. Mol. Mech. Mutagen. 379(1):1997;13-20.
45. You Y.H., Halangoda A., L Buettner V., Hill K., Sommer S.S., Pfeifer G. Mut. Res.-Genet. Toxicol. Environ. Mutagen. 420(1/3):1998;55-65.
46. Gossen J.A., Molijn A.C., Douglas G.R., Vijg J. Application of galactose-sensitive Escherichia-coli strains as selective hosts for lacZ-plasmid. Nucleic Acids Res. 20(12):1992;3254.
47. Tao K.S., Heddle J.A. The accumulation and persistence of somatic mutations in-vivo. Mutagenesis. 9(3):1994;187-191.
48. Deubel W., Bassukas I.D., Schlereth W., Lorenz R., Hempel K. Age dependent selection against HPRT deficient T lymphocytes in the HPRT+/- heterozygous mouse. Mut. Res.-Fundam. Mol. Mech. Mutagen. 351(1):1996;67-77.
49. Nishino H., Buettner V.L., Haavik J., Schaid D.J., Sommer S.S. Spontaneous mutation in Big Blue(R) transgenic mice: analysis of age, gender, and tissue type. Environ. Mol. Mutagen. 28(4):1996;299-312.
50. Andrew S.E., McKinnon M., Cheng B.S., Francis A., Penny J., Reitmar A.H., Jirik F.R. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1126-1130.
51. Toft N.J., Winton D.J., Kelly J., Howard L.A., Dekker M., Riele H.T., Arends M.J., Wyllie A.H., Margison G.P., Clarke A.R.C. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl. Acad. Sci. U. S. A. 96(7):1999;3911-3915.
52. Sands A.T., Suraokar M.B., Sanchez A., Marth J.E., Donehower L.A., Bradley A. P53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc. Natl. Acad. Sci. U. S. A. 92(18):1995;8517-8521.
53. Buettner V.L., Hill K.A., Nishino H., Schaid D.J., Frisk C.S., Sommer S.S. Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53 Big Blue double transgenic mice. Oncogene. 13(11):1996;2407-2413.
54. L.A. Loeb, Foundations in cancer research: cancer cells exhibit a mutator phenotype, Adv. Cancer Res. (1998) 25-26.
55. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin W.G., Levrero M., Wang J.Y.L. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 399(6738):1999;806-809.
56. Yuan Z.M., Shioya H., Ishiko T., Sun X.G., GuJ J.J., Huang Y.Y., Lu H., Kharbanda S., Weichselbaum R., Kufe D. P73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 399(6738):1999;814-817.
57. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362(6423):1993;849-852.
58. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362(6423):1993;847-849.
59. Griffiths S.D., Clarke A.R., Healy L.E., Ross G., Ford A.M., Hooper M.L., Wyllie A.H., Greaves T.I. Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene. 14(5):1997;523-531.
60. Clarke A.R., Gledhill S., Hooper M.L., Bird C.C., Wyllie A.H. P53 dependence or early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene. 9(6):1994;1767-1773.
61. Merritt A.J., Potten C.S., Kemp C.J., Hickman J.A., Balmain A., Lane D.P., Hall P.A. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal-tract of normal and p53-deficient mice. Cancer Res. 54(3):1994;614-617.
62. Merritt A.J., Allen T.D., Potten C.S., Hickman J.A. Apoptosis in small intestinal epithelia from p53-null mice: evidence for a delayed p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene. 14(23):1997;2759-2766.
63. C.S. Potten, A comprehensive study of the radiobiological response of the murine (Bdf1) small-intestine, Int. J. Radiat. Biol. 58 (6) (1990).
64. O.J. Sansom, A.R. Clarke, in preparation.
65. Potten C.S. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells. 15(2):1997;82-93.
66. Potten C.S., Booth C., Pritchard D.M. The intestinal epithelial stem cell: the mucosal governor. Int. J. Exp. Pathol. 78(4):1997;219-243.
67. Roberts S.A., Hendry J.H., Potten C.S. Deduction of the clonogen content of intestinal crypts - a direct comparison of 2-dose and multiple-dose methodologies. Radiat. Res. 141(3):1995;303-308.
68. Roberts S.A., Potten C.S. Clonogen content of intestinal crypts - its deduction using a microcolony assay on whole-mount preparations and its dependence on radiation-dose. Int. J. Radiat. Biol. 65(4):1994;477-481.
69. Hendry J.H., Cai W.B., Roberts S.A., Potten C.S. P53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat. Res. 148(3):1997;254-259.
70. Pritchard D.M., Potten C.S., Hickman J.A. The relationships between p53-dependent apoptosis inhibition of proliferation and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 58(23):1998;5453-5465.
71. Karran P., Bignami M. DNA-damage tolerance, mismatch repair and genome instability. Bioessays. 16(11):1994;833-839.
72. 6-benzlguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit p450-dependent activation of dacarbazine. Carcinogenesis. 21(4):2000;593-598.
73. Fazeli A., Stern R.G., Dickinson S.L., Bautista D., Dietrich W.F., Bronson R.T., Bresalier R.S., Lander E.S., Costa J., Weinberg R.A. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10199-10204.
74. Hundley J.E., Koester S.K., Troyer D.A., Hilsenbeck S.G., Subler M.A., Windle J.J. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol. Cell. Biol. 17(2):1997;723-731.
75. Symonds H., Krall L., Remington L., Saenzrobles M., Lowe S., Jacks T., Vandyke T. P53-dependent apoptosis suppresses tumor-growth and progression in-vivo. Cell. 78(4):1994;703-711.
76. Yin C.Y., Knudson C.M., Korsmeyer S.J., VanDyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385(6617):1997;637-640.
77. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379(6560):1996;88-91.
78. Clarke A.R., Cummings C., Harrison D.J. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene. 11(9):1995;1913-1920.
79. Schwartz D., Rotter V. P53 dependent cell cycle control: response to genotoxic stress. Semin. Cancer Biol. 8:1998;325-336.
80. Macleod K.F., Jacks T. Insights into cancer from transgenic mouse models. J. Pathol. 187(1):1999;43-60.
81. Wang X.J., Greenhalgh D.A., Jiang A.B., He D.C., Zhong L., Medina D., Brinkley B.R., Roop D.R. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene. 17(1):1998;35-45.